Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research note issued on Thursday.

What does this mean? Well, when the Sun ingresses into the final sign of the zodiac, it often marks the subtle end of a chapter in our lives. As we enter the final few weeks of the astrological ...